Catalent/CTLT

$55.48

-0.57%
-
1D1W1MYTD1YMAX

About Catalent

Catalent, Inc. is engaged in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The Company’s Biologics segment provides development and manufacturing of biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for complex oral solids, softgel formulations, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.

Ticker

CTLT

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Alessandro Maselli

Employees

17,800

Headquarters

Somerset, United States

Catalent Metrics

BasicAdvanced
$10.11B
Market cap
-
P/E ratio
-$7.18
EPS
1.17
Beta
-
Dividend rate
$10.11B
1.17397
$60.20
$31.45
2.71M
2.481
1.707
134.5
135.747
-0.63%
-12.32%
-30.28%
-14.02%
2.468
2.747
23.798
-13.38%
-433.95%
11.27%

What the Analysts think about Catalent

Analyst Ratings

Majority rating from 11 analysts.
Hold

Price Targets

Average projection from 10 analysts.
2.2% upside
High $63.50
Low $42.00
$55.48
Current price
$56.70
Average price target

Catalent Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-20.11% profit margin
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$1.02B
4.28%
Net income
$-206M
-72.86%
Profit margin
-20.11%
-73.98%

Catalent Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 1,055.57%
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
-$0.09
$0.09
-$0.10
-$0.24
-
Expected
-$0.03
$0.10
-$0.14
-$0.02
$0.20
Surprise
225%
-13.04%
-26.55%
1,055.57%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Catalent stock?

Catalent (CTLT) has a market cap of $10.11B as of April 20, 2024.

What is the P/E ratio for Catalent stock?

The price to earnings (P/E) ratio for Catalent (CTLT) stock is 0 as of April 20, 2024.

Does Catalent stock pay dividends?

No, Catalent (CTLT) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next Catalent dividend payment date?

Catalent (CTLT) stock does not pay dividends to its shareholders.

What is the beta indicator for Catalent?

Catalent (CTLT) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Catalent stock price target?

The target price for Catalent (CTLT) stock is $56.7, which is 2.2% above the current price of $55.48. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Catalent stock

Buy or sell Catalent stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing